Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its New Drug Application (NDA) for HRS‑7535 has been accepted by the National Medical Products Administration (NMPA) for blood glucose control in adults with type 2 diabetes. The filing advances Hengrui’s novel oral small‑molecule GLP‑1R agonist — a dual glucose‑ and weight‑targeting therapy — into the final regulatory stretch of one of China’s most competitive metabolic drug races.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | National Medical Products Administration (NMPA), China |
| Application Type | New Drug Application (NDA), accepted |
| Product | HRS‑7535, novel oral small‑molecule GLP‑1R agonist |
| Indication | Blood glucose control in adults with type 2 diabetes |
| Applicant | Jiangsu Hengrui Pharmaceuticals (SHA: 600276; HKG: 1276) |
| Next Steps | Regulatory review toward potential approval and commercial launch |
Drug Profile & Mechanism of Action
- Molecule: HRS‑7535, a novel oral small‑molecule glucagon‑like peptide‑1 receptor (GLP‑1R) agonist
- Peripheral Mechanism: Activates human GLP‑1R to stimulate insulin secretion, suppress glucagon secretion, and delay gastric emptying
- Central Mechanism: Acts on the central nervous system to enhance satiety, suppress appetite, and directly reduce energy intake
- Therapeutic Scope: Treats type 2 diabetes mellitus (T2DM) and manages weight, addressing two intertwined metabolic burdens in a single oral agent
Market Impact & Outlook
- Oral convenience edge: As an oral small‑molecule GLP‑1R agonist, HRS‑7535 offers a needle‑free alternative in a class dominated by injectables — a key adoption lever in China’s vast T2DM population
- Dual benefit profile: The combined glucose control and weight management mechanism positions HRS‑7535 to serve both glycemic and obesity‑adjacent demand, mirroring the global success of incretin therapies
- Incumbent scale: Hengrui Pharmaceuticals, China’s largest innovative pharma company by commercial reach, brings an unmatched domestic sales force and hospital access to the GLP‑1R class
- Competitive intensity: NDA acceptance places HRS‑7535 in a rapidly filling field of oral and injectable incretin candidates in China, where price, supply scale, and commercial execution will decide market share
Forward‑Looking Statements — This brief contains forward‑looking statements regarding the regulatory review timeline, approval prospects, and commercial potential of HRS‑7535 in type 2 diabetes and weight management. Actual results may differ materially due to regulatory, clinical, competitive, and market risks. No investment decision should be made solely on the basis of this brief.-Fineline Info & Tech
